Tag
Pharma / Healthcare
85 articles
Pharmaceutical companies are navigating a mixed landscape of progress and regulatory scrutiny. BioMarin saw its shares rise following positive Phase 3 trial results for a growth disorder treatment, signaling potential for future revenue growth and regulatory approvals. Conversely, Strides Pharma received a Form 483 from the USFDA with five observations, highlighting ongoing quality control challenges. Meanwhile, Anuh Pharma reported a 20% decline in net profit for fiscal year 2026, attributed to new labor code implementation and other factors. These developments underscore the inherent risks and opportunities within the sector, requiring investors to carefully assess both innovation and compliance factors.
BioMarin Shares Rise 4.8% on Trial Success
BioMarin's stock climbed 4.8% in after‑hours trading after its Phase 3 CANOPY‑HCH‑3 study met primary endpoint.
The trial showed a statistically significant 2.33 cm/yr increase in annualized growth ve
Anuh Pharma FY26 Net Profit at ₹41.05 Crore
Anuh Pharma reported audited FY26 net profit of ₹410.46 lakhs, a decrease from ₹473.52 lakhs in the previous year.
The Board recommended a final dividend of ₹1.50 per share (30%) for FY26, subject to
Strides Pharma Receives USFDA Form 483 with 5 Observations
Strides Pharma discloses completion of a routine USFDA cGMP inspection at its Bangalore flagship facility from May 12-20, 2026.
The USFDA issued a Form 483 containing five observations at the conclusi
Syngene International Seeks Shareholder Approval for Mazumdar-Shaw's Executive Role
Syngene International seeks shareholder approval via postal ballot to change Kiran Mazumdar-Shaw's role from Non-Executive to Executive Chairperson.
The special resolution proposes paying Ms. Mazumdar
Anuh Pharma FY26 Net Profit Declines 20% to ₹41.05 Crore
Anuh Pharma reported a 20% YoY decline in consolidated net profit to ₹41.05 crore for FY26, with revenue from operations at ₹772.56 crore.
The board recommended a final dividend of ₹1.50 per share (30
MedPlus Allots 82,419 ESOP Shares to Employees
MedPlus Health Services approved allotment of 82,419 equity shares to eligible employees under its ESOP 2021 plan.
The allotment increases paid-up share capital from ₹24.01 crore to ₹24.03 crore, addi
Mankind Pharma Singapore Investor Meetings May 25-26
Mankind Pharma management will conduct in-person investor meetings in Singapore on May 25-26, 2026.
The company confirmed no unpublished price sensitive information will be shared during these meeting
AstraZeneca Designates Materiality Determination KMPs
AstraZeneca Pharma India discloses its Key Managerial Personnel authorized to determine materiality for stock exchange disclosures as per SEBI LODR Reg. 30(5).
The designated personnel are MD Praveen
TAKE Solutions FY26 Net Profit ₹1,085 Lakhs, Income Up 496%
TAKE Solutions reported audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, approved by board on May 20, 2026.
Consolidated Total Income surged 495.68% YoY to ₹6,
Shree Ganesh Remedies Q4 FY26 Earnings Call Transcript
Shree Ganesh Remedies submitted its Q4 FY26 earnings call transcript to BSE for recordkeeping.
The earnings conference call was held on May 15, 2026, discussing quarterly financial performance.
The fu
Dadha Pharma LLP SLP Order: Counter-Affidavit Required
Supreme Court heard SLP filed by Dadha Pharma LLP against Commissioner of Income on 19‑May‑2026.
The petition challenges a 5‑April‑2023 High Court judgment in TCA No.1925/2008 concerning Dadha Pharma’
Dr. Agarwal's Health Care Gets ₹20.5 Cr GST Notice
Dr. Agarwal's Health Care received a GST show cause notice alleging ₹20.5 crore in discrepancies for FY 2023-24.
The notice from Chennai GST authorities cites output turnover differences, short tax pa
Zim Laboratories Q4 FY26 Earnings Call Recording Available
Zim Laboratories made the audio recording of its Q4 & FY26 earnings conference call available on its website.
The disclosure was made pursuant to SEBI Listing Regulations to comply with regulatory req
Indegene Schedules May 2026 Investor/Analyst Meets
Indegene Limited intimates a schedule of investor and analyst meetings from May 26-29, 2026, as per SEBI LODR regulations.
Meetings include a virtual 1x1 with Sundaram Mutual and in-person sessions at
Eris Lifesciences Q4 FY26 Earnings Call Recording Available
Eris Lifesciences made its Q4 and FY26 earnings conference call recording available on its website in regulatory compliance.
The call was held on May 20, 2026, to discuss audited standalone and consol
Dishman Carbogen Amcis Q4 FY26 Earnings Call Recording
Dishman Carbogen Amcis Ltd. submitted an audio recording of its investor conference call held on 20th May 2026 to BSE and NSE.
The call, which commenced at 15:00 IST, discussed the company's financial
Anthem Biosciences Q4 FY26 Earnings Call Recording
Anthem Biosciences submitted an SEBI Reg. 30 & 46 compliance filing regarding its FY26 earnings call.
The audio recording for the analyst call on audited Q4 and full-year FY26 results is now available
Alembic Limited IEPF Share Transfer Notice to Shareholders
Alembic Limited intimates exchanges of sending reminder letters to shareholders about unclaimed shares transferable to IEPF.
Shares on which dividends from FY 2018-19 to FY 2024-25 remain unclaimed ar
JHS Svendgaard Laboratories Board Meeting Intimation
JHS Svendgaard Laboratories intimates a board meeting on 26 May 2026 to approve audited financial results for Q4 and FY ended March 2026.
The trading window has been closed since 1 April 2026 and will
Titan Biotech Board Meeting on May 30, 2026
Titan Biotech Limited intimates BSE about its board meeting scheduled for May 30, 2026 to approve FY26 financial results.
The board will consider recommending dividend on equity shares for the financi
Supriya Lifescience Board Meeting on May 27, 2026
Board meeting scheduled for May 27, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend for FY 2025-26 during the meeting.
Trading
Hikal Q4 FY26 Earnings Conference Call Invite
Hikal Limited will hold a conference call on May 27, 2026, to discuss its Q4 and FY26 financial and operational performance.
The call will feature key management including Vice Chairman and Managing D
Alivus Life Sciences Intimates Investor Meetings
Alivus Life Sciences discloses two upcoming investor/analyst meetings scheduled for May 25 and 27, 2026.
Meetings include an in-person group conference with Ambit India and a one-on-one with Abakkus A
Emcure Schedules Analyst/Investor Meets May-June 2026
Emcure Pharmaceuticals intimates schedule for participation in multiple analyst and investor conferences from May to June 2026.
Meetings include group and one-on-one sessions at events hosted by Ambit
Glenmark's IGI Announces ISB 2301 Oncology Candidate
Ichnos Glenmark Innovation announced ISB 2301, a first-in-class multispecific antibody targeting solid tumors by activating T and NK cells.
The candidate targets three tumor-associated antigens and is
Mankind Pharma Q4 FY26 Investor Call Recording Available
Mankind Pharma makes audio recording of its Q4 & FY26 investor conference call available on its website.
The call was held on May 20, 2026, with senior management participation as previously intimated
Bharat Parenterals FY26 Transition Year, Innoxel Inflection
Bharat Parenterals reported FY26 as a transition year with consolidated revenue of ₹345.4 crore, flat YoY, but EBITDA surged 485% to ₹15.8 crore.
Subsidiary Innoxel Lifesciences grew 174% to ₹72.4 cro
IOL Chemicals FY26 Net Profit Up 36% YoY
Board approved audited standalone and consolidated financial results for Q4 and FY ended 31-Mar-2026, with statutory auditors issuing an unmodified opinion.
Standalone net profit for FY26 stood at ₹13
Kerala Ayurveda Board Meeting on May 25, 2026
Kerala Ayurveda Ltd schedules board meeting for May 25, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Trading window for insiders closed from March 31, 2026 and will r
Strides Pharma NCLT Approves Arco Lab Demerger
NCLT Bengaluru approved the demerger of Arco Lab's Life Sciences and Digital Innovation businesses into Pivot Path on May 18, 2026.
The scheme, effective from Appointed Date April 10, 2025, will make
Poly Medicure Schedules Q4 FY26 Earnings Call
Poly Medicure will hold an earnings call on May 25, 2026, to discuss audited financial results for Q4 and full year FY26.
The call will feature Managing Director Himanshu Baid, CFO Naresh Vijayvergiya
Senores Pharma May 25 Analyst Meetings
Senores Pharmaceuticals intimates BSE and NSE of its scheduled analyst and institutional investor meetings on May 25, 2026.
The physical meetings, hosted by Ambit Capital in Mumbai, will involve group
Aarti Pharmalabs Schedules Q4 FY26 Earnings Call
Aarti Pharmalabs schedules its Q4 FY26 earnings conference call for investors and analysts on May 26, 2026.
The call will feature Chairman Rashesh Gogri, MD Hetal Gogri Gala, and CFO Piyush Lakhani.
T
Anthem FY26 PAT Up 31% to ₹5,918 Mn
Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn with 15.2% YoY growth and PAT of ₹5,918 Mn with 31.1% YoY growth.
Q4FY26 revenue grew 26.4% YoY to ₹6,109 Mn with PAT surging 129.8%
Anthem FY26 Revenue Up 15% to ₹21,243 Mn
Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn, a 15.2% YoY growth, with CRDMO business leading at ₹17,727 Mn.
EBITDA for FY26 stood at ₹9,896 Mn with 43.4% margins, while PAT gre
Mankind Pharma Q4 Revenue Up 11.8%, EBITDA Margin 27.1%
Mankind Pharma reported Q4FY26 revenue of ₹3,443 Cr, up 11.8% YoY, with adjusted EBITDA margin expanding 400 bps to 27.1%.
Domestic business grew 13.4% driven by strong performance in cardiac (14.7%)
Mankind Pharma Q4 Revenue Up 11.8% YoY
Mankind Pharma reported Q4 FY26 revenue of ₹3,443 crore, an 11.8% YoY increase, with adjusted EBITDA margins at 27.1%.
Domestic business grew 13.4% YoY, driven by a 190 bps increase in chronic therapy
Anthem Biosciences FY26 KPI Disclosure: Revenue Growth, Margins
• Anthem Biosciences discloses audited KPIs for FY26 showing ₹21.24 billion revenue and 15.17% YoY growth.
• Material margin improved to ₹13.12 billion with EBITDA margin at 41.01% and PAT margin at 2
Anthem Biosciences FY26 PAT Up 31% to ₹5,918 Mn
Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn with 15.2% YoY growth and PAT of ₹5,918 Mn with 31.1% YoY growth.
Q4FY26 revenue grew 26.4% YoY to ₹6,109 Mn with PAT surging 129.8%
Anthem Biosciences Q4 Revenue Up 26% YoY
Anthem Biosciences reported its highest-ever quarterly revenue of ₹6,109 Mn in Q4FY26, a 26.4% YoY increase.
EBITDA surged 52.2% YoY to ₹3,184 Mn with margins expanding 600 bps to 48.1%, while PAT gre
Mankind Pharma Allots 80,872 ESOP Shares
Mankind Pharma allotted 80,872 equity shares under its 2022 ESOP plan following option exercises by an employee.
The allotment increased the company's paid-up share capital from 412.83 million to 412.
Shaily Engineering Q4 PAT Up 40% YoY
Shaily Engineering reported strong FY26 results with consolidated PAT up 83% YoY to ₹169.9 crore and revenue up 26% to ₹990.7 crore.
The company received a major ₹423 crore order for pen injectors and
Fermenta Biotech Board Meeting May 26 for FY26 Results
Fermenta Biotech's board will meet on May 26, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026.
The board will also consider recommending a fin
OneSource Q4 Revenue Up 47% on Semaglutide Launches
OneSource reported Q4 FY26 revenue of INR 4,282 million, a 47% sequential increase driven by the commercial launch of generic Semaglutide in India.
The company received approvals for its drug-device c
Amanta Healthcare Submits Q4 FY26 Earnings Call Recording
Amanta Healthcare Ltd submitted audio recording of Q4 FY26 earnings conference call to BSE and NSE.
Recording is available on company website for investor access as per regulatory requirement.
Submiss
ZIM Laboratories Q4 Net Profit Drops 23% YoY
ZIM Laboratories Board approved audited standalone and consolidated financial results for Q4 and FY26, reporting a 23% YoY drop in quarterly net profit.
Consolidated FY26 net profit fell 52% to ₹583.8
Gennex Laboratories Board Meeting May 30, 2026
Gennex Laboratories intimated a board meeting on May 30, 2026, to consider audited financial results for FY26.
The agenda includes adopting standalone and consolidated financial statements and reviewi
Senores Pharmaceuticals FY26 Revenue Up 62% PAT 108%
Senores Pharmaceuticals reported strong FY26 results with revenue growth of 62% to INR664 crore and PAT growth of 108% to INR122 crore.
Management provided FY27 guidance for 30-40% revenue growth and
Glenmark Board Meeting on May 29, 2026
Glenmark Pharmaceuticals board meeting scheduled for May 29, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend for FY2026 on equi
Zim Laboratories Appoints Cost Auditor for FY27
Zim Laboratories appointed M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27.
The appointment was approved by the Board of Directors in a meeting held on 19th May 2026.
The firm, regi
ZIM Laboratories FY26 Net Profit Declines 52% YoY
ZIM Laboratories approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2026, reporting a significant decline in annual profit.
Consolidated net profit fell 52% Yo
Orchid Pharma Q4 FY26 Earnings Call on May 26
Orchid Pharma schedules Q4 FY26 earnings call for May 26, 2026 at 4:30 PM IST hosted by Systematix Institutional Equities.
Management participants include MD Manish Dhanuka, Whole Time Director Mridul
Amanta Healthcare Q4 & FY26 Results Announcement
Amanta Healthcare reported FY26 revenue of ₹288 crore, a 5% YoY increase, with PAT surging 42% YoY to ₹15 crore.
Q4FY26 revenue grew 7% YoY to ₹77 crore, while PAT increased 28% YoY to ₹5.5 crore due
Amanta Healthcare FY26 PAT Jumps 42% to ₹15 Crore
Amanta Healthcare reported FY26 revenue of ₹288 crore, a 5% YoY increase, with PAT surging 42% to ₹15 crore.
EBITDA for the year stood at ₹63 crore, a 6% YoY rise, with margins improving to 22% from c
Orchid Pharma Board Meeting May 25 for FY26 Results
Orchid Pharma board meeting scheduled for May 25, 2026 to approve audited Q4 and FY26 financial results.
Trading window closed from April 1, 2026 until 48 hours after declaration of financial results.
Amanta Healthcare FY26 Net Profit Rises 43.6% YoY
Amanta Healthcare reported a 43.6% YoY increase in standalone net profit to ₹1,582.35 lakhs for FY26.
The company completed its IPO in Q2 FY25, raising ₹12,600 lakhs, with ₹5,246.75 lakhs remaining un
Anuh Pharma Nine Promoters Seek 0.95% Reclassification
Anuh Pharma received reclassification requests from nine promoter group members holding 0.95% total equity to become public shareholders.
The requests cite non-involvement in management and no control
Alkem Laboratories Board Meeting May 28 FY26 Results Dividend
Alkem Laboratories board meeting scheduled for May 28, 2026 to approve Q4 and FY26 audited financial results.
Board to consider recommendation of final dividend for financial year ended March 31, 2026
Novartis India Appoints Gowree Gokhale Independent Director
Novartis India shareholders approved the appointment of Ms. Gowree Gokhale as a Non-Executive Independent Director for a 5-year term via postal ballot.
The special resolution passed with 99.97% votes
Zydus Lifesciences Reappoints MD, Appoints Independent Director
Zydus Lifesciences Board approves reappointment of Dr. Sharvil P. Patel as Managing Director for 5 years effective April 1, 2027.
Board appoints Mr. Kulin S. Lalbhai as Additional and Independent Dire
Zydus Lifesciences Approves ₹1,100 Crore Share Buyback
Zydus Lifesciences board approved a ₹1,100 crore share buyback of up to 0.95% equity at ₹1,150 per share via tender offer.
The buyback size represents 5.16% and 3.84% of standalone and consolidated ne
Evexia Lifecare 34th AGM Voting Results Disclosure
Evexia Lifecare held its 34th AGM on May 15, 2026, with 11 resolutions passed via remote e-voting and e-voting.
All resolutions were approved, including financial statement adoption, director reappoin
Zydus Lifesciences Q4 Net Profit ₹12.7B, Recommends Dividend
• Board approved audited FY26 results with unmodified audit opinion from Deloitte Haskins & Sells LLP.
• Recommended a final dividend of ₹1 per share (100%) subject to shareholder approval at the AGM
Piramal Pharma Announces June 2026 Investor Meetings
Piramal Pharma discloses schedule of analyst and institutional investor meetings for May-June 2026 pursuant to SEBI LODR Regulation 30(6).
Five meetings scheduled with major financial institutions inc
Suven Life Sciences Responds to BSE Volume Query
Suven Life Sciences responds to BSE surveillance letter regarding recent stock volume movement.
Company confirms no material events requiring disclosure under SEBI LODR Regulation 30.
Attributes recen
OneSource Specialty Pharma FY26 Standalone Profit ₹212M
Auditor issued unmodified opinion on annual standalone results and unmodified conclusion on quarterly review for OneSource Specialty Pharma.
Standalone net profit for FY26 was ₹212.10 million, a signi
Windlas Biotech Reports Temporary Labor Protest Disruption
Windlas Biotech disclosed a temporary operational disruption due to statewide labor protests in Uttarakhand on May 18, 2026.
Production was restored by the evening shift with no material impact envisa
Dr. Reddy's Q4 FY26 Earnings Call Transcript Intimation
Dr. Reddy's Laboratories intimates exchanges of its Q4 FY26 earnings call transcript filing.
The transcript details the quarterly and annual results discussion held on May 12, 2026.
The document is a
Lupin Receives Tentative FDA Approval for Revefenacin
Lupin received tentative FDA approval for generic Revefenacin Inhalation Solution, 175 mcg/3 mL unit-dose vials.
The product is bioequivalent to Mylan's Yupelri® for COPD maintenance treatment with $2
Corona Remedies Q4FY26 PAT Surges 44% YoY
Corona Remedies held its Q4FY26 earnings call, reporting a 20.2% YoY revenue growth to INR 353 crore and a 44% YoY PAT surge to INR 45 crore.
Full-year FY26 revenue grew 17.3% to INR 1,403 crore with
Achyut Healthcare Board Meeting for FY2026 Results
Achyut Healthcare Ltd convenes board meeting on May 27, 2026 to approve audited financial results for Q4 and year ended March 31, 2026.
Agenda includes reviewing related party transactions, appointing
Windlas Biotech Schedules Q4 FY26 Earnings Call
Windlas Biotech will host an earnings call on May 22, 2026, to discuss Q4 and FY26 financial results.
Management participants include MD Hitesh Windlass and CEO & CFO Komal Gupta for the discussion.
T
Akums Q4 FY26 Results Call Audio Recording Intimation
Akums Drugs intimated exchanges about availability of audio recording for its Q4 FY26 and full-year FY26 results conference call held on May 18, 2026.
The company will share the transcript of the call
MPS Pharmaa Board Meeting for FY2026 Results on May 28
• MPS Pharmaa Limited's board will meet on May 28, 2026, to approve audited financial results for Q4 and FY ended March 31, 2026.
• The board will also consider appointing M/s Sanghi & Co. as internal
Aarti Drugs Uploads Q4 FY26 Earnings Call Recording
Aarti Drugs Ltd uploaded the audio recording of its Q4 and FY26 results conference call to the company website.
The conference call was held following the announcement of financial results for the qua
Strides Pharma Recommends Deloitte as New Auditor
Strides Pharma board recommends appointing Deloitte Haskins & Sells LLP as statutory auditors for a five-year term starting FY28.
The appointment will replace incumbent B S R & Co. LLP, which complete
Piramal Pharma Digwal Facility US FDA Inspection Closed
Piramal Pharma received an Establishment Inspection Report from the US FDA for its Digwal, Telangana manufacturing facility.
The US FDA inspection, initiated in February 2026, has been successfully cl
Ministry of Tribal Affairs Funds Rs 3.75 Crore CRISPR Therapy
Ministry of Tribal Affairs organized workshop on India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease.
Ministry provided Rs 3.75 crore financial assistance for the BIRSA 101 gene
HCP Investments Sells 7.5% Stake in Ind-Swift Laboratories
HCP Investments disclosed disposal of 6.5M shares (7.5% stake) in Ind-Swift Laboratories via open market sales from April 13-17, 2026.
The transaction reduces HCP's holding from 8.649% to 1.149% of In
Beta Drugs Gains Regulatory Approvals in Azerbaijan, Philippines
Beta Drugs Limited's manufacturing facility received GMP inspection from Azerbaijan's Ministry of Health, with approval expected within 1-2 months.
The company obtained Certificates of Product Registr
Amanta Healthcare Clarifies Promoter Share Acquisition Discrepancy
Amanta Healthcare submits a clarification to BSE and NSE regarding a prior disclosure about promoter share acquisition.
The company corrects that only 13,300 shares were credited to promoter Bhavesh P
Novartis AG Sells 70.68% Stake, No Encumbrance
Novartis AG discloses no encumbrance on its 1.75 crore equity shares in Novartis India as of March 31, 2026.
Reiterates its agreement to sell its entire 70.68% stake to three acquirers, as per the Feb
Amanta Healthcare Promoter Buys 28,800 Shares
Amanta Healthcare discloses Form C under SEBI Insider Trading Regulations for open market purchase by promoter.
Shri Bhavesh Patel, Promoter, CMD, acquired 28,800 equity shares on March 27 and March 3
Hannah Joseph Hospital Promoter Buys 3.84 Lakh Shares
Dr. Mosesjoseph Arunkumar, Promoter & MD, acquired 3,84,000 equity shares of Hannah Joseph Hospital Limited on 27.03.2026.
The acquisition was made on-market via BSE at a total transaction value of ₹2
Sudhir Sethi Acquires 7500 Beryl Drugs Shares
Beryl Drugs Limited discloses promoter Sudhir Sethi's acquisition of 7,500 equity shares (0.14%) via open market on 23 March 2026.
Post-acquisition, Sudhir Sethi's holding in Beryl Drugs rises from 9.